

1. Record Nr.	UNINA9910300086003321
Titolo	Dyslipidemias in Kidney Disease [[electronic resource] /] / edited by Adrian Covic, Mehmet Kanbay, Edgar V. Lerma
Pubbl/distr/stampa	New York, NY : , : Springer New York : , : Imprint : Springer, , 2014
ISBN	1-4939-0515-5
Edizione	[1st ed. 2014.]
Descrizione fisica	1 online resource (325 p.)
Disciplina	610 616 616.12 616.61
Soggetti	Nephrology Cardiology Internal medicine Internal Medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references at the end of each chapters and index.
Nota di contenuto	"" Atherogenic Dyslipidemia in CKD: Enhanced Disease Progression"" Renal Injury""; "" Vascular Injury""; "" Renal Pathophysiological Changes Driven by Atherogenic Dyslipidemia""; ""Oxidative Stress""; "" Endoplasmic Reticulum Stress""; "" Inflammatory Stress""; "" Mesangial Cell Proliferation and Matrix Expansion""; "" Inflammatory Stress Modifies Lipid Homeostasis""; ""Inflammation Changes Lipid Composition""; "" Inflammation Causes Cholesterol Redistribution""; "" The Impact of Statins on CKD""; ""Effect of Statins on Renal Protection: Evidence from CVD Trial"" "" Effect of Statins on Renal Protection: Evidence from CKD Trials"""" The Pleiotropic Effects of Statins""; "" Statin Resistance Under Inflammatory Stress""; "" How Long a Low LDL Cholesterol Status Should be Maintained?""; "" Conclusion""; ""References""; ""Chapter 3: Hyperlipidemia as a Risk Factor for Progression of CKD in Nondiabetics""; ""Introduction""; "" Lipid Abnormalities Secondary to CKD""; "" Pathogenesis of Kidney Injury due to Dyslipidemia""; "" Lipid

Abnormalities and Progression of CKD"; " Conclusion"; "References"
"Chapter 4: How Lipid-Lowering Agents Work: The Good, the Bad, and the Ugly"
"Introduction"; " Statins"; "Mechanism of Action"; " Effects of Statins"; " Statins in Predialysis CKD Patients"; " CKD Progression"; " Proteinuria"; "Statins in Dialysis Patients"; " Satins in Renal Transplant Patients"; " Tolerability and Safety of Statins"; " Fibric Acid Derivatives"; "Mechanism of Action"; " Effects of Fibrates"; " Tolerability and Safety of Fibrates"; " Cholesterol Absorption Inhibitors"; "Mechanism of Action"; " Effects of Ezetimibe"
" Tolerability and Safety of Ezetimibe"
" Nicotinic Acid"; "Mechanism of Action"; " Effects of Niacin"; " Tolerability and Safety of Niacin"; " Bile Acid Sequestrants"; "Mechanism of Action"; " Effect of Bile Acid Sequestrants"; " Tolerability and Safety of Bile Acid Sequestrants"; " Conclusion"; "References"; "Chapter 5: CVD in CKD: Focus on the Dyslipidemia Problem"; "Introduction"; " Definition and Classification of CKD"; " Association Between CKD and CVD-Epidemiological Data"; "In the General Population"
" In Patients with CV Risk Factors or Preexistent CVD"

Sommario/riassunto

Dyslipidemia in chronic kidney disease is a common clinical problem and growing in prevalence. With the recent publication of clinical practice guidelines on the management of lipid related disorders in patients affected by chronic kidney disease, an up-to-date and comprehensive resource of evidence-based literature is needed. Dyslipidemias in Kidney Disease captures the growing body of information on this subject matter. This book presents the latest clinical evidence and management guidance for patients of various demographics and stages of chronic kidney disease. Written for the nephrologist community, as well as cardiologists and general practitioners, this guide will provide practical knowledge and fill a much needed void in the literature. .
